Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Gain Therapeutics (GANX) to $8 from $10 but keeps a Buy rating on the shares. The company’s GT-02287 program exploring the agent’s therapeutic utility in iPD and GBA1-PD is continuing apace, with incremental data update expected in the upcoming GBA1 conference in Arizona this month, the analyst tells investors in a research note. Roth adds that upon FDA clearance, Gain is slated to begin a Phase 2 study in Q3 which could also involve a $60M equity financing.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GANX:
- Gain Therapeutics reports Q1 EPS (13c), consensus (14c)
- Gain Therapeutics management to meet with Maxim
- Reiterating Buy on Gain Therapeutics: Promising GT-02287 Parkinson’s Data and Diversified GCase Pipeline Support $8 Target
- Gain Therapeutics reports Q4 EPS (61c), consensus (14c)
- Gain Therapeutics Reports Promising GT-02287 Parkinson’s Data